111 related articles for article (PubMed ID: 18401307)
1. [Assessment of actual benefits of new drugs by the Transparency Committee].
Le Jeunne C
J Fr Ophtalmol; 2008 Jan; 31(1):90-3. PubMed ID: 18401307
[TBL] [Abstract][Full Text] [Related]
2. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of drug efficacy].
Massol J; Le Jeunne C
Presse Med; 2007 Mar; 36(3 Pt 2):505-11. PubMed ID: 17270386
[TBL] [Abstract][Full Text] [Related]
4. Relative Added Value: What are the Tools to Evalue it?
Jeunne CL; Woronoff-Lemsi MC; David N; Sahb Rd;
Therapie; 2008; 63(2):113-7. PubMed ID: 27393729
[TBL] [Abstract][Full Text] [Related]
5. Relative added value: what are the tools to evaluate it?
Le Jeunne C; Woronoff-Lemsi MC; David N; de Sahb R;
Therapie; 2008; 63(2):113-7, 107-11. PubMed ID: 18561884
[TBL] [Abstract][Full Text] [Related]
6. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
8. [Most innovative drugs labelled during the last years in paediatrics: does the paediatrician have the tools for their identification?].
Autret-Leca E
Arch Pediatr; 2010 Aug; 17(8):1237-42. PubMed ID: 20615673
[TBL] [Abstract][Full Text] [Related]
9. Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs.
Skipka G; Wieseler B; Kaiser T; Thomas S; Bender R; Windeler J; Lange S
Biom J; 2016 Jan; 58(1):43-58. PubMed ID: 26134089
[TBL] [Abstract][Full Text] [Related]
10. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
11. Value of post-registration studies for reimbursement renewal.
Molimard M; Bamberger M; Vray M
Therapie; 2009; 64(3):203-13. PubMed ID: 19671433
[TBL] [Abstract][Full Text] [Related]
12. [Role of drugs in therapeutic strategies].
Castaigne A
Rev Prat; 2002 Mar; 52(5):491-6. PubMed ID: 11949500
[TBL] [Abstract][Full Text] [Related]
13. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
15. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
Hörn H; Nink K; McGauran N; Wieseler B
Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
[TBL] [Abstract][Full Text] [Related]
16. [Early achievements of the Danish pharmaceutical industry-7].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2014; (42):31-62. PubMed ID: 25816561
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
18. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]